Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | MEN1 | O00255 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801454 | 1.00 | MIF (0.42) | MIFAURKAEGFRERBB2SRC | |
| SCHEMBL21048266 | 1.00 | MIF (0.42) | MIFAURKAEGFRERBB2SRC | |
| SCHEMBL29801391 | 0.88 | SENP8 (0.52) | SENP7SENP8SENP6MAPTMEN1 | |
| SCHEMBL21074342 | 0.88 | SENP8 (0.52) | SENP7SENP8SENP6MAPTMEN1 | |
| SCHEMBL21074343 | 0.88 | BACE1 (0.43) | MIFALKPIK3CAMTORSENP7 | |
| SCHEMBL19859149 | 0.88 | SENP7 (0.44) | ALKSENP7SENP8SENP6MAPT | |
| SCHEMBL29801683 | 0.88 | SENP7 (0.44) | ALKSENP7SENP8SENP6MAPT | |
| SCHEMBL29801540 | 0.88 | PRKCB (0.47) | EGFRERBB2PTK6SENP7SENP8 | |
| SCHEMBL21074378 | 0.88 | STING1 (0.43) | EGFRALKMAPK14SENP7SENP8 | |
| SCHEMBL29801537 | 0.88 | STING1 (0.43) | EGFRALKMAPK14SENP7SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12343335-B2 | Pharmaceutical composition for treating multiple sclerosis on basis of AMPK inhibitory function and zinc homeostasis control function | ZINCURE CORP. (KR) | 2025-07-01 | — | — | US | claimed |
| US-20230000839-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | ZINCURE CORP. (KR) | 2023-01-05 | — | — | US | claimed |
| EP-4066832-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | Zincure Corp. (KR) | 2022-10-05 | — | — | EP | claimed |
| WO-2021096270-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | 주식회사 진큐어 | 2021-05-20 | — | — | WO | claimed |
| US-12343335-B2 | Pharmaceutical composition for treating multiple sclerosis on basis of AMPK inhibitory function and zinc homeostasis control function | ZINCURE CORP. (KR) | 2025-07-01 | — | — | US | disclosed |
| US-20230000839-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | ZINCURE CORP. (KR) | 2023-01-05 | — | — | US | disclosed |
| US-20230000839-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | ZINCURE CORP. (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-4066832-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | Zincure Corp. (KR) | 2022-10-05 | — | — | EP | disclosed |
| EP-3498277-B1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | ZINCURE CORP (KR) | 2021-10-06 | — | — | EP | disclosed |
| WO-2021096270-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | 주식회사 진큐어 | 2021-05-20 | — | — | WO | disclosed |
| EP-3498277-A1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | Industry Academy Cooperation Foundation Of Sejong University (KR) | 2019-06-19 | — | — | EP | disclosed |
| US-20190167647-A1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | ZINCURE CORP. (KR) | 2019-06-06 | — | — | US | disclosed |
| US-20190167647-A1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | ZINCURE CORP. (KR) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000839-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | PRKAB1, PRKAB2, PRKAG1 | MIF 1463/4885AURKA 4445/4885EGFR 3810/4885 |
| US-20190167647-A1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | PRKAG1, PRKAB1, PRKAG2 | MIF 4423/4885AURKA 1674/4885EGFR 3119/4885 |
| US-12343335-B2 | Pharmaceutical composition for treating multiple sclerosis on basis of AMPK inhibitory function and zinc homeostasis control function | PRKAB1, PRKAB2, PRKAG1 | MIF 1463/4885AURKA 4445/4885EGFR 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.